This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Lannett Company, Inc. Emerges as a Private Company with New Board of Directors CI
Lannett Company, Inc. Emerged from Bankruptcy CI
First Amended Prepackaged Joint Plan of Reorganization and Disclosure Statement Approved for Lannett Company, Inc. CI
First Amended Prepackaged Joint Reorganization Plan Filed by Lannett Company, Inc. CI
Lannett Company, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
Motion for Joint Administration Approved for Lannett Company, Inc. CI
Combined Hearing for Disclosure Statement and Plan Approved for Lannett Company, Inc. CI
Global markets live: Ford, AMD, Starbucks, Estee Lauder, CVS Health.... Our Logo
Motion for Joint Administration Filed by Lannett Company, Inc. CI
Prepackaged Joint Reorganization Plan and Disclosure Statement Filed by Lannett Company, Inc. CI
Lannett Company, Inc. Filed for Bankruptcy CI
Lannett Company, Inc.(OTCPK:LCIN) dropped from S&P TMI Index CI
John Kozlowski Leaves Lannett Company, Inc. as Principal Accounting Officer, Effective May 16, 2023 CI
John Kozlowski Leaves Lannett Company, Inc. as Chief Financial Officer, Effective May 16, 2023 CI
Lannett Company, Inc. Announces Positive Results from Pivotal Clinical Insulin Trial CI
Top Premarket Gainers MT
Transcript : Lannett Company, Inc., Q2 2023 Earnings Call, Feb 01, 2023
Earnings Flash (LCI) LANNETT COMPANY Reports Q2 Revenue $80.9M MT
Earnings Flash (LCI) LANNETT COMPANY Posts Q2 Loss $-0.34 MT
Lannett Company, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
Lannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022 CI
Lannett Company, Inc. Raises Earnings Guidance for the Fiscal Year 2023 CI
Lannett to Implement 1-for-4 Reverse Stock Split MT
Lannett Company Provides Development Update on Biosimilar Insulin Products CI
Jeffrey Farber Announces Not to Stand for the Re-Election to the Board of Lannett Company, Inc CI
Chart Lannett Company, Inc.
More charts
Lannett Company, Inc. is engaged in the development, manufacturing, marketing and distribution of generic versions of brand pharmaceutical products. The Company markets approximately 100 products, mainly tablet, capsule or liquid oral generic medications. Its marketed products include generics such as Posaconazole, Fluphenazine, Levothyroxine, Sumatriptan and NDA-based product Numbrino. The Company's product portfolio include Amphetamine IR Tablets, which are used to treat Attention deficit hyperactivity disorder (ADHD) and narcolepsy; Dicyclomine tablets, used for the treatment of functional bowel disorder and irritable bowel syndrome; Levothyroxine Capsules, used to treat patients with hypothyroidism and other conditions, and Numbrino Nasal Solution, used for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults, among others.
More about the company
  1. Stock Market
  2. Equities
  3. LCI Stock
  4. News Lannett Company, Inc.
  5. Lannett : Submits Abbreviated New Drug Application to FDA for Generic Asthma Medication